Founded in 2018, Worg Pharmaceuticals is focused on creating innovative, safe and effective immunotherapy treatments targeting allergies and autoimmune diseases. Headquartered in Shanghai with an operational center in Basel, the company leverages two proprietary technology platforms, PCFiT and Apitope, to rapidly build its R&D pipeline. In addition to in-house development, Worg pursues external collaborations to enrich its portfolio and accelerate commercialization. The firm is also advancing a self-developed molecular allergy-diagnostics platform to complement its therapeutic offerings. Its management team draws experience from leading global life-science organizations such as Roche, Johnson & Johnson, Alexion, Shire, the FDA, Aventis, GSK, Boteng and Fosun. With these capabilities, Worg aims to evolve into a fully integrated, globally operating pharmaceutical company. No revenue or patient-usage metrics were disclosed in the article.

Total raised

$194M

Funding rounds

2

Latest round

Series D

Latest activity

Dec 2025